时间轴
克隆(Java方法)
药物开发
计算生物学
单克隆抗体
可制造性设计
计算机科学
过程开发
细胞培养
生物技术
生物信息学
医学
生物
药品
免疫学
抗体
药理学
工艺工程
工程类
遗传学
基因
历史
机械工程
考古
作者
Parimala Bolisetty,Gabi Tremml,Sen Xu,Anurag Khetan
出处
期刊:mAbs
[Landes Bioscience]
日期:2020-01-01
卷期号:12 (1): 1763727-1763727
被引量:26
标识
DOI:10.1080/19420862.2020.1763727
摘要
The importance of speed to clinic for medicines that may address unmet medical needs puts pressure on product development timelines. Historically, both toxicology and first-in-human clinical materials are generated using the same clonal-derived cells to ensure safety and minimize any development risks. However, cell line development with single cell cloning is time consuming, and aggravated by the time needed to screen for a lead clone based on cell line stability and manufacturability. In order to achieve faster timelines, we have used pools of up to six clones for earlier production of drug substance for regulatory filing-enabling toxicology studies, and then the final single clone was selected for production of clinical materials. This approach was enabled by using platform processes across all stages of early development, including expression vectors, host cell lines, media, and production processes. Through comprehensive cell culture and product quality analysis, we demonstrated that the toxicology material was representative of the clinical material for all six monoclonal antibody programs evaluated. Our extensive development experience further confirmed that using a pool of clones for toxicology material generation is a reliable approach to shorten the early development timeline.
科研通智能强力驱动
Strongly Powered by AbleSci AI